Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience-Reference-Cited by-同舟云学术

Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience

Published:1999-09 Issue:9 Volume:10 Page:1125-1128
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Faivre S.,Kalla S.,Cvitkovic E.,Bourdon O.,Hauteville D.,Dourte L.M.,Bensmaïne M.A.,Itzhaki M.,Marty M.,Extra J.M.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/10/9/1125/19477866/10-9-1125.pdf

Reference15 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N Engl J Med,1996

2. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin;Fink;Int J Cancer,1998

3. hMLHI expression and cellular responses of ovarian tumor cells to treatment with cytotoxic anticancer agents;Brown;Oncogene,1997

4. Phase I Study of oxaliplatin in patients with advanced cancer;Extra;Cancer Chemother Pharmacol,1990

5. Single-agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer;Chollet;Ann Oncol,1996

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity;Toxicology Letters;2015-09

2. Oxaliplatin for the treatment of ovarian cancer;Expert Opinion on Investigational Drugs;2015-06-30

3. A Phase II Nonrandomized Study of Oxaliplatin/Doxorubicin Combination Therapy in the Treatment of Recurrent Ovarian Cancer;Clinical Ovarian and Other Gynecologic Cancer;2013-12

4. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients;Journal of Experimental & Clinical Cancer Research;2013-08-08

5. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines;Biomedicine & Pharmacotherapy;2011-08